United States-based biotechnology company Sinopia Biosciences Inc. has entered a target discovery partnership with Japan-based Ono Pharmaceutical Co., Ltd. to advance treatments for a group of rare metabolic disorders representing significant unmet patient needs, according to a Business Wire report.

Sinopia will deploy its LEADS (LEarn And DiScover) platform, which uses metabolomics analysis to pinpoint and confirm new therapeutic targets addressing the biochemical deficiencies driving disease advancement.

Ono Pharmaceutical retains rights to progress any targets emerging from this work into clinical development and eventual commercialisation.

"This collaboration reflects the strength of Sinopia's metabolomics-based approach and the LEADS platform to uncovering novel therapeutic opportunities in genetically defined metabolic diseases," said Iman Famili, chief executive officer of Sinopia Biosciences.

"By partnering with Ono Pharmaceutical, we aim to expand the frontier of target discovery in rare metabolic disorders and help enable the development of meaningful new therapies for patients and families living with these devastating disorders."

The agreement provides Sinopia with research funding and an initial payment, alongside eligibility for performance-based milestone payments. Specific financial details remain confidential.

The arrangement demonstrates industry confidence in Sinopia's computational biology and machine learning capabilities for identifying drug development opportunities. The LEADS platform combines extensive omics datasets with artificial intelligence-driven network analysis to uncover treatment possibilities.

San Diego-based Sinopia is progressing several first-in-class development programmes addressing conditions with limited treatment options, with its most advanced candidate targeting Parkinson's disease. The company operates from JLABS facilities in California.

Discover the complete article on Sinopia Biosciences' target discovery platform and pharmaceutical collaboration strategy.